Long-acting muscarinic antagonist-+-long-acting beta agonist versus long-acting beta agonist-+-inhaled corticosteroid for COPD: A systematic review and meta-analysis

Respirology

Volumn 20, Issue 8, 2015, Pages 1153-1159

  Horita, Nobuyuki ^a,b   Miyazawa, Naoki ^a   Tomaru, Koji ^a   Inoue, Miyo ^a   Kaneko, Takeshi ^b  

^a SAISEIKAI YOKOHAMASHI NANBU HOSPITAL   (Japan)

^b YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

adverse effect; dyspnoea; exacerbation; forced expiratory volume; pneumonia

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; GLYCOPYRRONIUM BROMIDE; INDACATEROL; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; SALMETEROL; UMECLIDINIUM; VILANTEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; DELAYED RELEASE FORMULATION; DRUG COMBINATION;

ADULT; AGED; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; FORCED EXPIRATORY VOLUME; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; META ANALYSIS; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK; SCORING SYSTEM; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYSTEMATIC REVIEW; ADVERSE EFFECTS; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DRUG COMBINATION; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; BRONCHODILATOR AGENTS; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FORCED EXPIRATORY VOLUME; HUMANS; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84945490680     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12603     Document Type: Review

References (32)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) The Global Strategy for the Diagnosis, Management and Prevention of COPD, 2014. [Accessed 20 on October 20th, 2014.] Available from URL: http://www.goldcopd.org/
2. Frampton JE,. QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease. Drugs 2014; 74: 465-488.
3. Schachter EN,. Indacaterol/glycopyrronium bromide fixed-dose combination for the treatment of COPD. Drugs Today (Barc.) 2013; 49: 437-446.
4. 2-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2013; 11: CD003794.
5. Hanania NA,. The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD. Pulm. Pharmacol. Ther. 2008; 21: 540-550.
6. Suissa S, Barnes PJ,. Inhaled corticosteroids in COPD: the case against. Eur. Respir. J. 2009; 34: 13-16.
7. Malerba M, Morjaria JB, Radaeli A,. Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD-role of umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis. 2014; 9: 687-695.
8. Scott LJ, Hair P,. Umeclidinium/Vilanterol: first global approval. Drugs 2014; 74: 389-395.
9. Vogelmeier CF, Bateman ED, Pallante J, Alagappan VK, D'Andrea P, Chen H, Banerji D,. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir. Med. 2013; 1: 51-60.
10. Zhong N, Wang X, Zhou N, Zhang F, Patalano F, Humphries M, Wang L, Banerji D,. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/fluticasone combination (SFC) in patients with COPD: the LANTERN study. Int. J. Chron. Obstruct. Pulmon. Dis. 2015; 10: 1015-1026.
11. GlaxoSmithKline. A study to compare the efficacy and safety of umeclidinium/vilanterol and fluticasone propionate/salmeterol in subjects with chronic obstructive pulmonary disease (COPD): (NCT01817764/DB2114930). 2014. [Accessed 27 Dec 2014.] Available from URL: https://clinicaltrials.gov/ct2/show/NCT01817764
12. GlaxoSmithKline. A study to compare the efficacy and safety of umeclidinium/vilanterol with fluticasone propionate/salmeterol in subjects with chronic obstructive pulmonary disease (COPD): (NCT01879410/DB2114951). 2014. [Accessed 27 Dec 2014.] Available from URL: https://clinicaltrials.gov/ct2/show/NCT01879410.
13. GlaxoSmithKline. A study to evaluate the efficacy and safety of umeclidinium bromide/vilanterol compared with fluticasone propionate/salmeterol over 12 weeks in subjects with chronic obstructive pulmonary disease (COPD) (NCT01822899/DB2116134). 2014. [Accessed 27 Dec 2014.] Available from URL: https://clinicaltrials.gov/ct2/show/NCT01822899
14. Hoshino M, Ohtawa J, Akitsu K,. Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair in chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 2014; 14: pii: S1094-5539, 00091-1. European Respiratory Society, abstract 700090; Session 281; Date: September 8 2014.
15. Magnussen H, Paggiaro P, Schmidt H, Kesten S, Metzdorf N, Maltais F,. Effect of combination treatment on lung volumes and exercise endurance time in COPD. Respir. Med. 2012; 106: 1413-1420.
16. Rabe KF, Timmer W, Sagkriotis A, Viel K,. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008; 134: 255-262.
17. Donohue JF, Worsley S, Zhu CQ, Hardaker L, Church A,. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir. Med. 2015; 109: 870-881.
18. Chalmers TC, Smith H Jr, Blackburn B, Silverman B, Schroeder B, Reitman D, Ambroz A,. A method for assessing the quality of a randomized control trial. Control. Clin. Trials 1981; 2: 31-49. May.
19. Higgins PJ, Green S,. Cochrane Handbook for Systematic Reviews of Interventions (Version 5.1.0). The Cochrane Collaboration, London. 2011. [Accessed 20 Oct 2014.] (Available from URL: http://handbook.cochrane.org/front-page.htm).
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
21. American Thoracic Society. Minimal Clinically Significant Difference. 2007. Available from URL: http://qol.thoracic.org/sections/measurement-properties/minimal-clinically-significant-difference.html
22. Jones PW,. St. George's Respiratory Questionnaire: MCID. COPD 2005; 2 (Suppl. 1): 75-79.
23. Mahler DA, Witek TJ Jr,. The MCID of the transition dyspnea index is a total score of one unit. COPD 2005; 2: 99-103.
24. Horita N, Kaneko T,. Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan. Int. J. Chron. Obstruct. Pulmon. Dis. 2015; 10: 813-822.
25. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J,. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356: 775-789.
26. Yang IA, Clarke MS, Sim EH, Fong KM,. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012; (7): CD002991.
27. Global Initiative for Asthma (GINA) Global Strategy For Asthma Management and Prevention. 2014. [Accessed 1 Nov 2014.] Available from URL: http://www.ginasthma.org/local/uploads/files/GINA-Report-2014-Aug12.pdf
28. Global Initiative for Asthma. Diagnosis of Diseases of Chronic Airflow Limitation: Asthma COPD and Asthma-COPD Overlap Syndrome (ACOS). 2014. [Accessed 1 Nov 2014.] Available from URL: http://www.ginasthma.org/local/uploads/files/AsthmaCOPDOverlap.pdf
29. Horita N, Kaneko T,. Triple therapy vs. dual bronchodilator therapy for chronic obstructive pulmonary disease: is it worth the cost? Respir. Investig. 2015; 53: 173-175.
30. Price D, West D, Brusselle G, Gruffydd-Jones K, Jones R, Miravitlles M, Rossi A, Hutton C, Ashton VL, Stewart R, et-al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis. 2014; 9: 889-904.
31. Drivenes E, Ostrem A, Melbye H,. Predictors of ICS/LABA prescribing in COPD patients: a study from general practice. BMC Fam. Pract. 2014; 15: 42.
32. White P, Thornton H, Pinnock H, Georgopoulou S, Booth HP,. Overtreatment of COPD with inhaled corticosteroids-implications for safety and costs: cross-sectional observational study. PLoS ONE 2013; 8: e75221.